Reported data are for both sexes combined and for individuals aged 25 years and older. Shading indicates 95% uncertainty intervals.
Reported data are for both sexes combined and for individuals aged 25 years and older. The boxes show the median and extend from the 25th to the 75th percentiles. The upper whiskers extend from the third quartile to the highest value within 1.5 × the IQR of the third quartile; the lower whiskers extend from the first quartile to the lowest value within 1.5 × the IQR of the first quartile. Data outside the the whisker range are plotted as open circles.
aCategory includes rheumatic heart disease, hypertensive heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, peripheral vascular disease, endocarditis, and other cardiovascular and circulatory diseases.
Reported data include both sexes combined.
aIncludes rheumatic heart disease, hypertensive heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, peripheral vascular disease, endocarditis, and other cardiovascular and circulatory diseases.
Reported data include both sexes combined and individuals aged 25 years and older. Data are reported for the 3 most populous countries (United States, China, and India) to highlight burden at the highest population levels and utility of country-specific results. Data for other countries and regions are presented on a regional scale using super regions from the Global Burden of Diseases, Injuries, and Risk Factors study 2015 (the regions that contain the United States, China, and India were excluded to prevent double representation of the following results: high income, South Asia, Southeast Asia, East Asia, and Oceania) and have presented the remainder of countries from those super regions as an additional group. The boxes show the median and extend from the 25th to the 75th percentiles. The upper whiskers extend from the third quartile to the highest value within 1.5 × the IQR of the third quartile; the lower whiskers extend from the first quartile to the lowest value within 1.5 × the IQR of the first quartile. Data outside the whisker range are plotted as open circles.
aCategory includes 45 countries.
eAppendix. Overview and Methods
eTable 1. Relative Risks Used by Age
eTable 2. Mean Systolic Blood Pressure (mm Hg) by Sex and by Age in 1990 and 2015 for All Countries
eTable 3. Estimated Number of Deaths and Disability-Adjusted Life-Years (DALYs) in Thousands Related to Systolic Blood Pressure ≥110-115 mm Hg and Systolic Blood Pressure ≥140 mm Hg for All Causes Combined
eTable 4. Estimated Age-Standardized Rates of Deaths and Disability-Adjusted Life-Years (DALYs) per 100 000 Related to Systolic Blood Pressure ≥110-115 mm Hg and Systolic Blood Pressure ≥140 mm Hg for All Causes Combined
eFigure 1. Age-Specific Relative Risks
eFigure 2. Global Map of Age-Standardized Mean Systolic Blood Pressure for Both Sexes Combined in 2015
eFigure 3. Global Map of the Percent Change of Age-Standardized Mean Systolic Blood Pressure (mm Hg) from 1990-2015 for Both Sexes Combined
eTable 5. Relative Risk Input Data and Estimates by Age
eTable 6. Estimated Age-Standardized Rates of Deaths and Disability-Adjusted Life-Years (DALYs) per 100 000 Related to Systolic Blood Pressure ≥110-115 mm Hg and Systolic Blood Pressure ≥140 mm Hg for All Causes Combined for Males and Females in 1990 and 2015 for Global, SDI Groupings, 8 Super Regions, 21 Regions, and at the Country and Territory Level With 95% Uncertainty Interval
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Hassen Abate K, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Bärnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang Y, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, Zaki MES, Murray CJL. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-182. doi:10.1001/jama.2016.19043
What is the worldwide association between elevated blood pressure and the burden of disease?
In studies from 154 countries that included 8.69 million participants, it is estimated that between 1990 and 2015 the rate of systolic blood pressure (SBP) of at least 110 to 115 mm Hg increased from 73 119 to 81 373 per 100 000 persons, and SBP of 140 mm Hg or higher increased from 17 307 to 20 526 per 100 000 persons. The estimated rate of annual deaths associated with SBP of of at least 110 to 115 mm Hg increased from 135.6 to 145.2 per 100 000 persons, and for SBP of 140 mm Hg or higher increased from 97.9 to 106.3 per 100 000 persons.
Over the past 25 years, the number of individuals with worldwide SBP levels of at least 110 to 115 mm Hg and of 140 mm Hg or higher and the estimated associated deaths have increased substantially.
Elevated systolic blood (SBP) pressure is a leading global health risk. Quantifying the levels of SBP is important to guide prevention policies and interventions.
To estimate the association between SBP of at least 110 to 115 mm Hg and SBP of 140 mm Hg or higher and the burden of different causes of death and disability by age and sex for 195 countries and territories, 1990-2015.
A comparative risk assessment of health loss related to SBP. Estimated distribution of SBP was based on 844 studies from 154 countries (published 1980-2015) of 8.69 million participants. Spatiotemporal Gaussian process regression was used to generate estimates of mean SBP and adjusted variance for each age, sex, country, and year. Diseases with sufficient evidence for a causal relationship with high SBP (eg, ischemic heart disease, ischemic stroke, and hemorrhagic stroke) were included in the primary analysis.
Main Outcomes and Measures
Mean SBP level, cause-specific deaths, and health burden related to SBP (≥110-115 mm Hg and also ≥140 mm Hg) by age, sex, country, and year.
Between 1990-2015, the rate of SBP of at least 110 to 115 mm Hg increased from 73 119 (95% uncertainty interval [UI], 67 949-78 241) to 81 373 (95% UI, 76 814-85 770) per 100 000, and SBP of 140 mm Hg or higher increased from 17 307 (95% UI, 17 117-17 492) to 20 526 (95% UI, 20 283-20 746) per 100 000. The estimated annual death rate per 100 000 associated with SBP of at least 110 to 115 mm Hg increased from 135.6 (95% UI, 122.4-148.1) to 145.2 (95% UI 130.3-159.9) and the rate for SBP of 140 mm Hg or higher increased from 97.9 (95% UI, 87.5-108.1) to 106.3 (95% UI, 94.6-118.1). Loss of disability-adjusted life-years (DALYs) associated with SBP of at least 110 to 115 mm Hg increased from 148 million (95% UI, 134-162 million) to 211 million (95% UI, 193-231 million), and for SBP of 140 mm Hg or higher, the loss increased from 95.9 million (95% UI, 87.0-104.9 million) to 143.0 million (95% UI, 130.2-157.0 million). The largest numbers of SBP-related deaths were caused by ischemic heart disease (4.9 million [95% UI, 4.0-5.7 million]; 54.5%), hemorrhagic stroke (2.0 million [95% UI, 1.6-2.3 million]; 58.3%), and ischemic stroke (1.5 million [95% UI, 1.2-1.8 million]; 50.0%). In 2015, China, India, Russia, Indonesia, and the United States accounted for more than half of the global DALYs related to SBP of at least 110 to 115 mm Hg.
Conclusions and Relevance
In international surveys, although there is uncertainty in some estimates, the rate of elevated SBP (≥110-115 and ≥140 mm Hg) increased substantially between 1990 and 2015, and DALYs and deaths associated with elevated SBP also increased. Projections based on this sample suggest that in 2015, an estimated 3.5 billion adults had SBP of at least 110 to 115 mm Hg and 874 million adults had SBP of 140 mm Hg or higher.
Systolic blood pressure (SBP) of at least 110 mm Hg has been related to multiple cardiovascular and renal outcomes, including ischemic heart disease, cerebrovascular disease, and chronic kidney disease.1- 3 The global obesity epidemic may further increase SBP in some populations.4- 6 The burden of SBP of at least 110 mm Hg remains high despite the availability of preventive interventions and low-cost, effective antihypertensive medications.4,7
Several studies have assessed SBP measurements from population-based examination surveys.4,5 The global burden related to high SBP has been reported in detail for 1997, 2001, 2005, and 2010.5,6,8,9 Results from the Global Burden of Disease, Injuries, and Risk Factor study 2015 (GBD 2015) related risk factors to 41% of all disability-adjusted life-years (DALYs) in 2015.10 In GBD 2015, SBP was associated with the highest burden among risk factors—more than either smoking or obesity.10 In the current study, we used the results of the GBD 2015 comparative risk assessment to explore patterns of SBP above 110 to 115 mm Hg and related deaths and DALYs for 195 countries and territories from 1990 to 2015.10 This analysis reports separately the disease burden for participants aged 25 years and older related to SBP levels of at least 110 to 115 mm Hg and SBP levels of 140 mm Hg or higher.11,12
This analysis supersedes all previous global burden of disease study results for SBP because all data from 1990 to present have been re-analyzed using consistent methods.
This analysis was part of the GBD 2015 comparative risk assessment to assess health loss (DALYs) related to specific risk factors.9 In contrast to pooling studies or primary studies that analyze individual record data to estimate the magnitude of related burden and the number of people at different levels of SBP, the GBD study is a descriptive meta-analysis of available study results. Thus, the data are projections for a population rather than direct estimates for a sample population and should be assessed considering the availability of primary data for a given country and year, uncertainty of the pooled estimates, and the overall modeling strategy and assumptions.
Quiz Ref IDPrior to the 1990s, diastolic blood pressure was considered to be a better predictor of health outcomes than SBP. Later, epidemiological studies showed a greater association and better predictive validity with outcomes for SBP, especially for patients who were older (in whom incidence of related disease is higher).13,14 Atherosclerosis is known to increase SBP and strengthen the association with heart, central nervous system, and renal vascular diseases.15- 17 Due to the strong correlation between SBP and diastolic blood pressure and to avoid double counting of high blood pressure burden, measures of SBP alone are now used in studies of the global and national burdens of risk factors. Only SBP was included in this analysis. For this study, estimates were first produced at age-, sex-, country-, year-, and cause-specific strata before being aggregated.
The analysis was divided into 5 components in the following sequence: (1) the distribution (mean and variance) of SBP in each age, sex, and country group was estimated; (2) the relative risks (RRs) of 10 cardiovascular and renal outcomes, including chronic kidney disease, associated with SBP of at least 110 to 115 mm Hg based on pooled prospective cohort studies were estimated; (3) a level of minimum risk for SBP was determined; (4) the cause-specific population-attributable fraction (PAF) related to SBP that was elevated above this minimum level of risk was calculated; and (5) deaths and DALYs related to SBP of at least 110 to 115 mm Hg were computed by multiplying each outcome by the PAF for each country, age, sex, and year group.
Data for this study were obtained from an update to the systematic review of health examination surveys reporting SBP originally conducted as part of the GBD 2010 study.9,18 Using PubMed, studies published between July 15, 2009, and December 31, 2015, were added to the original review. Studies were included if they were population-based and measured SBP using a sphygmomanometer (either manual or electronic; see eAppendix in the Supplement for details on the evaluation of study quality and identifying and removing outliers). All measurements of blood pressure were categorized by sex, and data points were divided by age groups based on the global age distribution of mean SBP using the available detailed age- and sex-specific data. Mean SBP was estimated in each age-, sex-, country-, and year-specific stratum using spatiotemporal Gaussian process regression (method has been widely applied in global health estimation, including for tobacco prevalence estimation and obesity).19,20 Detailed methods for this estimation procedure are described in the eAppendix (Supplement) and country data sources are provided in searchable form online through the Global Health Data Exchange.21
The standard deviation of SBP was estimated for every age, sex, country, and year by estimating the relationship between the mean of SBP and the standard deviation in available studies; the proportion of variance of SBP due to measurement error was also estimated (eAppendix in the Supplement).22- 27 SBP varies over time with circadian rhythm, changes in diet, physical activity, and treatment, which add substantial random noise to the long-term exposure average.28 Random measurement error of SBP also causes an attenuation of the association between the SBP level and incidence of disease outcomes called regression dilution bias.29 A correction for usual SBP is commonly used in cohort studies to estimate the association between the level of SBP and the outcome risk. Using these corrected RRs in burden of disease estimates requires the same adjustment be applied to the distributions of SBP from surveys that are based on 2 to 3 measurements taken during a single encounter. Multiple measurements in a cohort of participants over time can provide an estimate of the random variation that needs to be taken out of the single (time) measurement to correct for this underestimation of effect size.
The GBD comparative risk assessment framework pairs each risk with known disease-specific outcomes. To be paired, sufficient evidence for a causal relationship between risk and disease outcome is needed. The strength of evidence for association between risk-outcome pairs, including elevated SBP, was evaluated as part of the GBD 2015 study (see eAppendix in the Supplement for detailed methods of the risk-outcome evaluation).10 On the basis of analysis from pooled cohort studies,30 the following diseases were identified as having sufficient evidence to support a relationship with high SBP (≥110-115 mm Hg): ischemic heart disease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease, cardiomyopathy, atrial fibrillation, aortic aneurysm, rheumatic heart disease, peripheral vascular disease, endocarditis, chronic kidney disease, and other cardiovascular diseases (CVDs [cardiovascular outcomes other than those previously listed]). Although the cause of rheumatic heart disease and endocarditis is infection, high SBP has been associated with an increasing risk of death, accelerating adverse heart effects caused by infection or autoimmune response. The aggregated outcome was assumed to include death and morbidity.
Cohort studies and a meta-analysis of 147 clinical trials of blood pressure–lowering drugs found improved outcomes due to blood pressure lowering were similar across the range of 120 to 180 mm Hg SBP levels at pretreatment.31,32 The RRs that were based on blood pressure lowering in these meta-analyses were similar to the results from the Prospective Studies Collaboration.33 For the present study, age-specific RRs for cardiovascular outcomes based on pooled cohort studies were used including the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration (eFigure 1 and eTable 1 in the Supplement).18,34 For this study, a meta-analysis of cohort studies was completed to estimate the relationship between SBP and chronic kidney disease. Citation information for the data sources used for RRs are provided by the Global Health Data Exchange in a searchable web tool.21
The GBD comparative risk assessment framework is based on the observation that risk caused by a given exposure begins at a certain level and then ascends as exposure increases above that level. This counterfactual level is referred to as the theoretical minimum-risk exposure level which, when compared with an observed level of SBP, allows for estimation of the PAF. The theoretical minimum-risk exposure level of SBP was estimated to range from 110 to 115 mm Hg based on pooled prospective cohort studies that show risk of mortality increases for SBP above that level.30,35 Recent randomized clinical trial results, including the Systolic Blood Pressure Intervention Trial (SPRINT) and the Heart Outcomes Prevention Evaluation (HOPE-3), show that lifestyle modification early in life is likely to be a major component for lowering SBP to near this level given the variable range of benefit observed in these studies when blood pressure was lowered with antihypertensive medications alone.36- 38 The selection of a theoretical minimum-risk exposure level of an SBP level of 110 to 115 mm Hg—the level that captures the maximum attributable burden—is consistent with the GBD study approach of estimating all attributable health loss that could be prevented even if current interventions did not exist that could achieve such a change in exposure level (eg, a tobacco-smoking prevalence of 0%). Some studies, such as the Framingham cohort, have found an increase in SBP with increasing age and it has been suggested that the theoretical minimum-risk exposure level should also follow this age pattern.39 Other studies that found no change in SBP with age40- 42 support maintaining a single theoretical minimum-risk exposure level across age groups. Based on the current evidence,43 we determined that a difference in theoretical minimum-risk exposure level by age group was not sufficiently supported and decided to retain a single level across age groups. Further investigations in the form of cohorts or pooled cohort studies are needed to determine if varying the theoretical minimum-risk exposure level for SBP with age group is justified. To include the uncertainty in the theoretical minimum-risk exposure level, 1000 random draws from the uniform distribution of the interval between 110 and 115 mm Hg were taken; unertainty in the theoretical minimum-risk exposure level was propagated by sampling between the 110- and 115-mm Hg interval each time the population-attributable burden was calculated.
The equation in this section describes the formula used for computing a PAF for a continuous risk factor; the PAF for SBP in an age-sex-country-year for a cause (o) is defined as follows:
RRoas(x) is the relative risk as a function of exposure level (x) for SBP, cause (o), age group (a) and sex (s). Pasct (x) is the distribution of exposure of SBP in age group (a), sex (s), country (c), and year (t). The lowest level of exposure (l) and the highest level of exposure possible (u) (300 mm Hg) are also described in this equation. The log-normal function, rather than normal,44 β, or γ distributions, gave the best fit of the distribution of SBP in multiple health examination surveys such as the US National Health and Nutrition Examination Survey (NHANES), China Longitudinal Healthy Longevity Survey, and Indonesia Family Life Survey.
Deaths and DALYs related to SBP of at least 110 to 115 mm Hg were computed by multiplying an age-, sex-, country-, year-, and cause-specific PAF by the estimated deaths or DALYs for the same strata. Total (all-causes) burden related to SBP of at least 110 to 115 mm Hg was calculated by the following:
Hypertensive heart disease and hypertensive chronic kidney disease were treated as conditions that would not have occurred without elevated systolic blood pressure, and all disease burden for these causes was attributed to this risk factor. The PAFs and related deaths and DALYs for each 1-mm Hg increment of SBP were evaluated to provide the distribution of health burden across the range of possible SBP levels.
We computed 95% uncertainty intervals (UIs) for all estimates of deaths and DALYs related to SBP of at least 110 to 115 mm Hg. A Monte Carlo simulation approach was used to propagate uncertainty from all sources in the final burden estimations. These intervals incorporated sampling uncertainty in the examination surveys, parameter estimation in the spatiotemporal Gaussian process regression model for blood pressure mean, the RRs for each outcome from the analysis of pooled cohort studies, the theoretical minimum-risk exposure level, and the deaths and DALYs estimated for each age, sex, country, year, and cause. The 1000 draws of the posterior distribution of mean SBP and outcomes by country, age, and sex were calculated independently so the variance of estimation for the aggregate groups (eg, all-age, both sexes, or global burden) were more likely to be underestimated because of possible covariance between different risk levels and outcome, countries, or sexes. Despite efforts to incorporate all sources of uncertainty, uncertainties from some intermediate predictive steps were not propagated due to existing data and methodological constraints. Therefore, the UIs presented may be optimistic estimates. Analyses and computations were completed using Stata version 13.1, R version 3.1.2, and Python version 2.7.11.
In total, 844 studies from 154 countries (N=8.69 million individual participants) published from 1980 to 2015 were included in GBD 2015.10 Between 1990 and 2015, the rate of SBP of at least 110 to 115 mm Hg increased from 73 119 (95% UI, 67 949-78 241) to 81 373 (95% UI, 76 814-85 770) per 100 000; the rate of SBP of 140 mm Hg or higher increased from 17 307 (95% UI, 17 117-17 492) to 20 526 (95% UI, 20 283-20 746) per 100 000. The associated estimated annual deaths for SBP of at least 110 to 115 mm Hg and of 140 mm Hg or higher increased from 135.6 deaths (95% UI, 122.4-148.1) to 145.2 deaths (95% UI 130.3-159.9) per 100 000 and from 97.9 deaths (95% UI, 87.5-108.1) to 106.3 deaths (95% UI, 94.6-118.1) per 100 000.
Table 1 shows the projected number of individuals, deaths, and DALYs related to SBP of at least 110 to 115 mm Hg and SBP of 140 mm Hg or higher for 6 time points between 1990 and 2015. The projected number of individuals with SBP of at least 110 to 115 mm Hg increased from 1.87 billion (95% UI, 1.74-2.0 billion) in 1990 to 3.47 billion (95% UI, 3.27-3.65 billion) in 2015, and the associated annual number of projected deaths increased from 7.2 million (95% UI, 6.5-7.9 million) in 1990 to 10.7 million (95% UI, 9.6-11.8 million) in 2015, a 1.6% increase per year (Table 1). Projected DALYs related to SBP of at least 110 to 115 mm Hg increased from 148 million (95% UI, 134-162 million) in 1990 to 211 million (95% UI 193-231 million) in 2015. The projected number of individuals with SBP of 140 mm Hg or higher increased from 442 million (95% UI, 437-447 million) in 1990 to 874 million (95% UI, 864-884 million) in 2015, and the associated annual number of projected deaths in 2015 (7.8 million [95% UI, 7.0-8.7 million]) or 14.0% of total deaths (95% UI, 12.5%-15.5%) and 143 million DALYs (95% UI, 130.2-157.0 million) were related to SBP of 140 mm Hg or higher.
Similar to DALYs, age-standardized death rates associated with SBP of at least 110 to 115 mm Hg declined from 225 (95% UI, 200-247) per 100 000 to 170 (95% UI, 151-188) per 100 000 (eTable 4 in the Supplement), which suggests population growth and aging may have been the main driver of the observed increase in total projected DALYs related to SBP of at least 110 to 115 mm Hg since 1990 (Table 1). Age-standardized rate per capita (an adjusted measure for population size and age structure) of deaths and DALYs related to SBP of at least 110 to 115 mm Hg decreased despite increased average SBP. The downward change in the age-standardized rate of deaths was 0.92% (95% UI, 0.80%-1.03%) per year for men and 1.37% (95% UI, 1.26%-1.50%) per year for women (eTable 6 in the Supplement). Age-standardized DALYs per capita decreased from 4.1 (95% UI, 3.7-4.5) per 100 persons in 1990 to 3.2 (95% UI, 2.9-3.4) per 100 persons in 2015 (see data reported as per 100 000 individuals in eTable 4 in the Supplement).
Figure 1 shows 2 views of global trends for individuals with SBP of 140 mm Hg or higher. Panel A shows that the rate of high SBP of 140 mm Hg or higher increased from 17 307 (95% UI, 17 116.9-17 492) per 100 000 in 1990 to 20 525 (95% UI, 20 283-20 746) per 100 000 in 2015. Although the rate initially decreased between 1990 and 1995, the initial trend was followed by an increase to 2015. Panel B shows that after controlling for changes in population aging, the age-standardized rate increased after 2000 (eFigure 2 and eFigure 3 in the Supplement).
Figure 2 shows the distribution of DALYs in the world by level of SBP and by cause. At the global level, 29% of DALYs related to SBP of at least 110 to 115 mm Hg occurred in individuals who had SBP between 115 and 140 mm Hg. Another 26% of DALYs occurred in individuals with SBP between 140 and 150 mm Hg, and the remaining 45% of DALYs occurred in individuals with SBP 150 mm Hg or higher. At all levels of SBP, ischemic heart disease was the most important contributor to SBP-related deaths followed by hemorrhagic stroke and then ischemic stroke.
Projected global deaths and DALYs associated with SBP of at least 110 to 115 mm Hg and SBP of 140 mm Hg or higher by specific outcome and the PAFs for those outcomes in 2015 are shown in Table 2. Forty-one percent (95% UI, 35.9%-45.4%) of deaths related to SBP of 140 mm Hg or higher were related to CVDs (and the rest through chronic kidney disease), among which 40.1% (95% UI, 32.2%-48.1%) were related to ischemic heart disease, 40.4% (95% UI, 34.5%-46.4%) to cerebrovascular diseases (38.1% [95% UI, 29.9%-46.7%] to ischemic stroke and 42.5% [95% UI, 34.2%-50.8%] to hemorrhagic stroke) (death PAFs for SBP ≥140 mm Hg; Table 2). SBP of at least 110 to 115 mm Hg was associated with all hypertensive heart disease deaths, 68.7% (95% UI, 63.7%-73.5%) of chronic kidney disease deaths, 54.4% (95% UI, 46.8%-62.4%) of cerebrovascular disease deaths (50.0% [95% UI, 39.4.0%-60.8%] of ischemic stroke and 58.3% [95% UI, 48.0%-68.5%] of hemorrhagic stroke deaths), and 54.5% (95% UI, 44.4%-64.2%) of ischemic heart disease deaths (Table 2). Overall, SBP of 140 mm Hg or higher was associated with 73.2% (95% UI, 71.5%-75.0%) of all SBP-related deaths of at least 110 to 115 mm Hg, or 14.0% (95% UI, 12.5%-15.5%) of global deaths (Table 2).
Table 3 shows projected deaths and DALYs associated with SBP 110 to 115 mm Hg and higher and SBP of 140 mm Hg and higher by age and sex. With increasing cardiovascular DALYs as reported by age, SBP-related deaths and DALYs increase substantially (Table 3). Deaths and DALYS increased by age beginning with 2.5 million DALYs related to SBP of at least 110 to 115 mm Hg for men aged 25 to 29 years, 1.1 million DALYs for women in that age group, and increasing to 11.0 million DALYs for men aged 80 years and older, and 15.6 million DALYs for women in that age group. The total burden is greater in men than women except after age 75, when more burden is observed in women because of longer life expectancy. Among those aged 60 years and older, more than 66% of burden is in those with SBP of 140 mm Hg or higher, whereas among those aged 25 to 29 years, 30% of CVD burden is in those with SBP of 140 mm Hg or higher.
Figure 3 shows age-standardized DALY rates associated with SBP of at least 110 to 115 mm Hg for 21 GBD regions and by cause. Regions were ordered by life expectancy. Age-standardized DALY rates varied substantially—from 1025.66 (95% UI, 916.51-1136.97) in the Asia-Pacific high-income region to 7022.18 (95% UI, 5259.73-9652.2) in Oceania. The variation in 2015 for SBP of at least 110 to 115 mm Hg was greater across countries ranging from 923 DALYs (95% UI, 794-1046) per 100 000 in Switzerland to 13 639 (95% UI, 10 696-17 151) per 100 000 in Afghanistan (eTable 4 in the Supplement). Age-standardized DALYs associated with SBP of at least 110 to 115 mm Hg were highest in Oceania, Eastern Europe, Central Asia, and Central sub-Saharan Africa. Relative to life expectancy, the burden of SBP was comparatively high in East Asia and Central Europe (eTable 4 in the Supplement). The relative contributions of different outcomes to the global age-standardized DALY rate associated with SBP of at least 110 to 115 mm Hg varied by region. In sub-Saharan Africa, cerebrovascular diseases predominated, while in Oceania, Central Asia, and Eastern Europe, ischemic heart disease predominated.
Table 4 and Table 5 provide deaths and DALYs associated with SBP 110 to 115 mm Hg and of 140 mm Hg or higher for all ages and both sexes combined, by region, and for the 25 most populous countries in the world from 1990 to 2015. The last column in Table 4 and Table 5 lists the number of individuals measured for each country for all included data sources. Estimates for all countries can be found in eTables 2, 3, and 4 in the Supplement. The highest age-standardized death rate was estimated for Afghanistan with 637 deaths (95% UI, 511-579) per 100 000, Vanuatu with 420 (95% UI, 309-584) per 100 000, and Iraq with 415 (95% UI, 336-506) per 100 000. The lowest age-standardized rates of SBP-related deaths were in Andorra with 61 (95% UI, 51-71) per 100 000, France with 62 (95% UI, 54-72) per 100 000, and Canada with 64 (95% UI, 53-75) per 100 000. The age-standardized mortality rate for women was 145 (95% UI, 129-162) per 100 000 vs 197 (95% UI, 176-217) per 100 000 for men (eTable 6 in the Supplement).
Of the global burden of 212 million DALYs related to SBP of at least 110 to 115 mm Hg, 60% occurred in 10 countries, with the majority of DALYs in China with 45.1 million and in India with 38.7 million (Figure 4). Age-standardized DALYs from SBP decreased globally, but the trend varied between countries. Although age-standardized DALYs per capita associated with SBP of at least 110 to 115 mm Hg decreased between 1990 and 2015 in South Korea by 77.2% (95% UI, 75.6%-78.8%) and in the the United Kingdom by 65.6% (95% UI, 64.1%-67.1%), a significant increase of 18.9% (95% UI, 1.6%-41.4%) was observed in Bangladesh. Countries in sub-Saharan Africa (except Southern sub-Saharan Africa), South Asia, Central Asia, Southeast Asia, and Central Latin America generally increased in age-standardized DALYs per capita associated with SBPs of at least 110 to 115 mm Hg. In China, the total burden of SBP has increased since 1990, and SBP levels increased after 1995 but were offset by decreases in mortality until 2005, at which point the overall age-standardized burden started increasing.
Quiz Ref IDIn this study, we used an expanded set of blood pressure prevalence surveys to assess, for the first time to our knowledge, the full distribution of the population by level of SBP and the burden of mortality and DALYs associated with each level of SBP for 195 countries and territories. This study showed that SBP of at least 110 to 115 mm Hg was associated with more than 10 million deaths (95% UI, 9.6-11.8 million) and more than 212 million DALYs (95% UI, 193-231 million) in 2015, a 1.4-fold increase since 1990. Compared with all other specific risks quantified in the GBD, SBP of at least 110 to 115 mm Hg was the leading global contributor to preventable death in 2015.10 These estimates are concerning given that in 2015, an estimated 3.5 billion individuals had an SBP level of at least 110 to 115 mm Hg.
This analysis, the first to be performed at a comprehensive global scale, found considerable variation among the 195 countries and territories and 21 regions studied. Five countries accounted for more than half of global DALYs associated with SBP of at least 110 to 115 mm Hg: China, India, Russia, Indonesia, and the United States. Both the projected number and prevalence rate of SBP of at least 110 to 115 mm Hg are likely to continue to increase globally. These findings support increased efforts to control the burden of SBP of at least 110 to 115 mm Hg to reduce disease burden.
Quiz Ref IDIn this study, ischemic heart disease and stroke accounted for the majority of health loss (DALYs, which include deaths and nonfatal burden) related to SBP of at least 110 to 115 mm Hg. Although the majority of the burden associated with SBP occurred in persons with hypertension (SBP ≥140 mm Hg), nearly 30% occurred in individuals with an SBP between 115 and 140 mm Hg. A broad range of other conditions contributed to health loss associated with SBP of at least 110 to 115 mm Hg, with chronic kidney disease notable for contributing almost as many DALYs globally in 2015 as hypertensive heart disease.
There have been claims that the burden of SBP of at least 110 to 115 mm Hg is an increasing problem globally.4,5,8,45 The finding that the total projected number of individuals with SBP of 140 mm Hg or higher is increasing globally supports those claims. Quiz Ref IDAlthough the drivers of trends in hypertension were not quantified in this study, other research has documented that dietary salt intake, fruit and vegetable consumption, overweight and obesity, and physical activity have also changed substantially over the same time period.10 Among these factors at the global scale, the prevalence of obesity and overweight in particular increased substantially over the period 1990 to 2015.20
With population growth and aging and the fact that SBP levels increase with age, the number of persons with hypertension and related adverse health outcomes are expected to increase in the world. Despite the increase in global SBP levels in terms of numbers (per individual with SBP ≥140 mm Hg), rates, and age-standardized rates of SBP of 140 mm Hg or higher, deaths and DALYs associated with SBP of at least 110 to 115 mm Hg and SBP of 140 mm Hg or higher have decreased. The difference in trends between exposure to SBP of at least 110 to 115 mm Hg and the rates of related outcomes is likely related to background trends downward in global age-specific cardiovascular death rates. Previous studies have attributed those declines in CVD death rates to changes in risk factors such as tobacco as well as improved access to treatment.46- 48 Although declines in elevated blood pressure may have contributed to CVD declines in some high-income countries such as Japan, globally, the downward trend in hypertension is not a driver of CVD rate reductions.49 Yet SBP of at least 110 to 115 mm Hg remains one of the larger risks for decreased human health, greater than tobacco or high body mass index, for which SBP probably mediates a portion of the risk.9 Prevention and control of high blood pressure through a combination of behavioral, lifestyle, and drug treatment strategies as a health system priority could mitigate the growing burden associated with high SBP.
The results of the current study are informed by, but do not help to resolve, the significant debate about appropriate clinical use and targets for blood pressure–lowering medications. Meta-analyses performed by Law et al and Ettehad et al showed cardiovascular mortality benefits for a target SBP as low as 120 mm Hg.31,32 SPRINT showed significant mortality benefits among individuals in the United States with elevated cardiovascular risk, 90% of whom were already receiving prior treatment with blood pressure–lowering medication, when they received intensive blood pressure reduction therapy and achieved an average SBP below 120 mm Hg.38 The HOPE-3 trial did not observe this same benefit when less intensive blood pressure reduction was achieved. However, unlike the SPRINT trial, the population enrolled in HOPE-3 had an initial mean SBP of 138 mm Hg (and only 22% were receiving prior treatment with blood pressure–lowering medications), more tobacco smokers, and more women. In a prespecified analysis, HOPE-3 found benefit only among those whose SBP remained above 143 mm Hg.
Quiz Ref IDThese results support the model assumption that elevated SBP is a modifiable risk factor for mortality even though the precise subpopulation and SBP target for blood pressure–lowering medications remains less clear. The purpose of this study was to estimate the full extent of health burden lost related to elevated SBP and not to determine the optimum SBP level for the current population. This estimation is an essential step in understanding the contribution of SBP as a risk factor for global health loss. Quantification of the modifiable health loss due to SBP, given scale-up of the technologies currently available for SBP lowering, would require an alternate estimation strategy than used for this study. However in 2015, 7.8 million deaths and 143 million DALYs were estimated to be related to SBP of 140 mm Hg or higher, suggesting that large health gains from expanded treatment with blood pressure–lowering medications are possible. It is likely that more evidence will be needed to define the role of pharmacotherapy in reducing the burden associated with SBP of at least 110 mm Hg and less than an SBP of 140 mm Hg.
This study has important limitations. First, the burden of high diastolic blood pressure, including cases of isolated high diastolic blood pressure, was not included. Second, burden was only associated with SBP for individuals aged 25 years and older, except for hypertensive heart disease, which included all ages. Third, estimates of population mean SBP were based on 814 studies in 154 countries. For 41 countries with no examination survey data, estimates of blood pressure levels were based on spatiotemporal Gaussian process regression statistical models; there is a need for population-based health surveys in these countries as well as broader implementation of surveys that track access to treatment. Fourth, measured standard deviations of blood pressure were converted to narrower ranges of usual blood pressure using a single correction factor based on cohort studies in 5 countries.10 The conversion from measurements taken at a given point in time to usual blood pressure were based on an intertemporal variation in SBP for each individual. This intertemporal variation may well vary across countries. Moreover, uncertainty in this correction was not captured in this study. Fifth, the relative risk of each 10-mm increment of SBP was assumed to be the same from 115 mm Hg to SBP above 200 mm Hg. The meta-analyses by Lv et al and by Law et al of all blood pressure–lowering trials support this assumption; showing that there was no statistically different RR as a function of starting level of SBP.31,50 Sixth, the RRs for each outcome were assumed to be generalizable across populations. Higher RRs have been reported for 6 countries in the East Asia, high-income Asia Pacific, and Australasia regions including China (and Hong Kong), Japan, New Zealand, Singapore, South Korea, and Taiwan.35,51,52 Other studies found RRs varied by race.7,53,54 Large cohort pooling studies are required to establish statistically significant location- and time-specific RRs. While acknowledging these limitations, this study was based on the largest available set of data and applied the same methods to previous years to provide a consistent analysis of time trends from 1990 to 2015.
In international surveys, although there is uncertainty in some estimates, the prevalence of elevated SBP (≥110-115 and ≥140 mm Hg) increased substantially between 1990 and 2015, with a corresponding increase in DALYs and deaths associated with elevated SBP. Projections based on this sample suggest that in 2015, an estimated 3.5 billion adults had SBP of at least 110 to 115 mm Hg and 874 million adults had SBP of 140 mm Hg or higher.
Corresponding Author: Christopher J. L. Murray, DPhil, Institute for Health Metrics and Evaluation, 2301 Fifth Ave, Ste 600, Seattle, WA 98121 (firstname.lastname@example.org).
Correction: This article was corrected on January 19, 2017, for incorrect values in the Abstract and for missing units of measure in Table 1.
Author Contributions: Drs Murray and Forouzanfar had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Forouzanfar, Biryukov, Bekele, Jonas, Khosravi, Kim, Kokubo, Lopez, Mokdad, Moran, Nawaz, Sampson, Shiue, Uthman, Murray.
Acquisition, analysis, or interpretation of data: Forouzanfar, Liu, Roth, Ng, Biryukov, Marczak, Alexander, Estep, Hassen Abate, Akinyemiju, Ali, Alvis-Guzman, Azzopardi, Banerjee, Bärnighausen, Basu, Bekele, Bennett, Biadgilign, Catalá-López, Feigin, Fernandes, Fischer, Gebru, Gona, Gupta, Hankey, Jonas, Judd, Khang, Kimokoti, Kolte, Lotufo, Malekzadeh, Melaku, Mensah, Misganaw, Mokdad, Neal, Ngalesoni, Ohkubo, Pourmalek, Rafay, Rai, Rojas-Rueda, Santos, Sawhney, Schutte, Sepanlou, Shifa, Tedla, Thrift, Tonelli, Truelsen, Tsilimparis, Ukwaja, Uthman, Vasankari, Venketasubramanian, Vlassov, Vos, Westerman, Yan, Yano, Yonemoto, Zaki, Murray.
Drafting of the manuscript: Forouzanfar, Liu, Marczak, Estep, Kim, Malekzadeh, Mokdad, Sawhney, Uthman, Vos, Yonemoto, Zaki.
Critical revision of the manuscript for important intellectual content: Forouzanfar, Liu, Roth, Ng, Biryukov, Marczak, Alexander, Estep, Hassen Abate, Akinyemiju, Ali, Alvis-Guzman, Azzopardi, Banerjee, Bärnighausen, Basu, Bekele, Bennett, Biadgilign, Catalá-López, Feigin, Fernandes, Fischer, Gebru, Gona, Gupta, Hankey, Jonas, Judd, Khang, Khosravi, Kimokoti, Kokubo, Kolte, Lopez, Lotufo, Malekzadeh, Melaku, Mensah, Misganaw, Moran, Nawaz, Neal, Ngalesoni, Ohkubo, Pourmalek, Rafay, Rai, Rojas-Rueda, Sampson, Santos, Sawhney, Schutte, Sepanlou, Shifa, Shiue, Tedla, Thrift, Tonelli, Truelsen, Tsilimparis, Ukwaja, Uthman, Vasankari, Venketasubramanian, Vlassov, Vos, Westerman, Yan, Yano, Yonemoto, Zaki, Murray.
Statistical analysis: Forouzanfar, Liu, Roth, Ng, Biryukov, Alexander, Hassen Abate, Ali, Bennett, Fischer, Gebru, Mokdad, Nawaz, Sawhney, Sepanlou, Ukwaja, Vos, Zaki.
Administrative, technical, or material support: Forouzanfar, Roth, Marczak, Estep, Bekele, Biadgilign, Catalá-López, Fernandes, Jonas, Judd, Khang, Kim, Malekzadeh, Melaku, Mokdad, Neal, Ngalesoni, Rojas-Rueda, Sawhney, Schutte, Shifa, Tedla, Thrift, Tsilimparis, Ukwaja, Vasankari, Yan, Zaki.
Review results: Rafay.
Scientific oversight as former chair of the Cardiovascular Disease Expert Panel: Mensah.
Additional comments: Kokubo.
Collecting and providing materials as a source of information: Melaku.
Reviewing and providing data: Bekele.
Study rationale checking and future directions for research, practice, and policy: Shiue.
Review of content during internal review efforts: Bärnighausen.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ng reports receipt of grants from the Bill and Melinda Gates Foundation during the conduct of the study and receipt of personal fees from IBM Watson Health outside the submitted work. Dr Hankey reports receipt of honoraria from AC Immune for chairing the data safety monitoring committee, Bayer for lecturing, and Medscape Web MD for participating in a discussion outside the submitted work. Dr Lotufo reports receipt of honoraria for lectures from Abbvie Brazil outside the submitted work. Dr Santos reports receipt of a grant from the São Paulo Research Foundation. Dr Schutte reports receipt of personal fees from Boehringer-Ingelheim for developing educational material and Omron Healthcare and Aspen Pharmaceuticals for presentations outside the submitted work. Dr Thrift reports receipt of grants from the National Health and Medical Research Council during the conduct of the study. Dr Vos reports receipt of a grant from the Bill and Melinda Gates Foundation during the conduct of the study. Dr Yan reports receipt of grant support from the National Natural Sciences Foundation of China.The remaining authors report no disclosures.
Funding/Support: This research was supported by funding from the Bill and Melinda Gates Foundation.
Role of the Funder/Sponsor: The Bill and Melinda Gates Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.